Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial
[470] As we stated earlier in this rule and in prior rules, we believe MRF users (for example innovators, researchers, employers) will use this data to analyze and draw more meaningful comparisons of hospital standard charge information, identify outliers and encourage market competition, support more effective contract negotiations, and develop downstream tools to support patient price comparisons
This advancement offers patients a convenient, needle-free option that doesn't require refrigeration, potentially making effective weight management accessible to more people who may have been hesitant about injections or faced barriers to using injectable medications
Challenges and limitations The specificity of RNA therapies is crucial, as their effectiveness depends on strong on-target activity with minimal off-target or unintended on-target effects